Karyopharm Therapeutics Strengthens Workforce to Drive Cancer Treatment Innovations

Karyopharm Therapeutics Expands Workforce to Enhance Cancer Treatment Innovations

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company focused on innovative oncology therapies, strengthens its workforce by granting 333 restricted stock units (RSUs) to a newly hired employee. This strategic move, effective September 30, 2025, is executed under the company's 2022 Inducement Stock Incentive Plan and complies with Nasdaq Listing Rule 5635(c)(4). The RSUs are designed to vest over three years, with one-third of the shares vesting on each anniversary of the grant date, contingent upon the employee’s ongoing service at Karyopharm. This initiative not only incentivizes employee retention but also aligns with the company's goal to attract top talent in the competitive field of cancer therapy development.

Karyopharm has established itself as a pioneering entity in the oncology sector, particularly with its flagship product, XPOVIO® (selinexor), recognized as the first oral exportin 1 (XPO1) inhibitor approved in the United States. Initially aimed at treating multiple myeloma, XPOVIO® is now marketed for three oncology indications and has also received regulatory approval in 50 international markets, including Europe, the U.K. (under the name NEXPOVIO®), and China. This global reach underscores the company’s commitment to making innovative cancer therapies accessible to patients worldwide. Karyopharm’s strategic focus remains on developing groundbreaking oral compounds that target nuclear export dysregulation, a critical mechanism in cancer progression.

As Karyopharm continues to expand its pipeline, it remains dedicated to addressing high unmet needs in various cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). The company’s mission is propelled by a profound respect for the resilience of cancer patients, driving them to enhance treatment options and improve patient outcomes. By fostering a collaborative and innovative workplace culture, Karyopharm aims to attract and retain the best minds in the industry, ensuring the company remains at the forefront of cancer treatment advancements.

In addition to its recent workforce expansion, Karyopharm maintains an active presence in the pharmaceutical industry, engaging with stakeholders through various channels. The company invites interested parties to learn more about its initiatives and development pipeline via its website and social media platforms, including LinkedIn and X. As Karyopharm continues to advance its innovative therapies, the emphasis on building a strong team reflects its commitment to making significant strides in cancer care.